Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Impact of Lung Cancer-derived Fibroblasts on Mast Cells Activation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02161523
Recruitment Status : Completed
First Posted : June 11, 2014
Last Update Posted : March 22, 2018
Sponsor:
Information provided by (Responsible Party):
Meir Medical Center

Brief Summary:

In addition to their role in allergic inflammation, mast cells are often found at the site of tumors. They have been attributed both to pro- and anti-tumorigenic roles depending on the tumor type. Secretion of mast cell mediators such as histamine, tryptase, fibroblast growth factor (b-FGF), vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) can enhance tumor growth and angiogenesis while TNF-a and heparin act as tumor suppressors.

The non-small cell lung cancer constitutes the majority of cases of lung cancer. In lung cancer, mast cell numbers correlate with tumor angiogenesis and poor prognosis.

In this work, we are interested to determine the factors in lung cancer microenvironment that attribute to mast cell activation. Beside the tumor cells themselves, the cancer microenvironment includes other cells such as fibroblasts. The fibroblasts arising from tumor stroma, called cancer-associated fibroblasts (CAFs), undergo activation, and have different feature compared to normal fibroblasts (NFs). In this work we are interested to determine whether CAF cells derived from lung tumors, together with the lung cancer cells, or microvesicles-derived from these cells, are able to stimulate mast cells to degranulate and/ or to release various cytokines and chemokines.

For this propose, during surgery of patients with lung cancer, we will take unnecessary sample from the cancer and from normal area for purification of CAF or normal fibroblast cells. Those cells will be co-cultured with both lung cancer cell line (A-549) or microvesicles-derived from these cells, and human mast cell line (LAD2). Supernatants will be collected for determine degranulation and cytokine release from these mast cells.


Condition or disease
Lung Cancer

Layout table for study information
Study Type : Observational
Actual Enrollment : 20 participants
Observational Model: Other
Time Perspective: Prospective
Actual Study Start Date : July 1, 2014
Actual Primary Completion Date : June 1, 2015
Actual Study Completion Date : June 1, 2015

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Measuring the levels of b-hexosaminidase (marker for mast cells degranulation ) and the cytokines levels [ Time Frame: 1-2 weeks ]

Biospecimen Retention:   Samples Without DNA
Biopsy from lung tissue


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patient with non small cell lung carcinoma that need a surgery without connection to this experiment
Criteria

Inclusion Criteria:

Patient with non small cell lung carcinoma

Exclusion Criteria:

none

Layout table for additonal information
Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT02161523    
Other Study ID Numbers: 0059-14-MMC
0059-14-MMC ( Other Identifier: Meir Medical Center )
First Posted: June 11, 2014    Key Record Dates
Last Update Posted: March 22, 2018
Last Verified: March 2018
Keywords provided by Meir Medical Center:
mast cells, lung cancer, cancer associated fibroblasts (CAF)
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases